KMT2A and leukemia: Among the derivatives, the optimized antagonist 16 days (compound 90 in Figure 5) was the most potent inhibitor against WDR5-MLL1 with the Kdisp value of 60 nM, which offered novel therapeutic options in the treatment of leukemia harboring MLL fusion proteins.